Fig. S1

а



b





Fig S1: Indole suppresses activation of splenic CD11b⁺ cells by suppressing Akt and ERK signaling pathway

a, Effect of indole (1mM) on the Akt and ERK signaling pathways in CD11b⁺ cells (monocytes/macrophages) in different post incubation time. Figure depicts the flow cytometric dot-plot analysis and time-course graphical representation of phospho-Akt and phospho-ERK expression in CD11b⁺ cells . **b,** Schematic diagram of murine CIA model used for results depicted in Fig 3c to Fig 3g. Mice were inoculated with an emulsion of CFA and collagen on Day 0 followed by bacterial treatment on Day 7 and Treg transfer on Day 14. A booster (repeat) injection of CFA + Collagen was administered to the mice on Day 21 to enhance CIA.

Fig. S2







- CD19 hi CD62L lo
- CD19 hi CD40L hi
- CD19 hi PD-1 mid CTLA4 hi
- CD19 hi CD140hi
- CD19 hi PD-1 lo CD40L lo

Fig. S2: Bm $\Delta v j b R$::tnaA activates T_{reg} cells and modulates B-cell mediated inflammation.

a, BMDMs infected with either Bm $\Delta v j b R$::*tnaA* or Bm $\Delta v j b R$ were co-cultured with CD4⁺T cells from mouse LNs and spleen and activated by using anti-CD3/CD28 Abs. Flow cytometric dot-plot assay shows that Bm $\Delta v j b R$::*tnaA* treated BMDMs greatly promoted expression of FoxP3 and PD-1 and production of IL-10 in CD4⁺T cells. The dot-plots are followed by graphical representation from 3 independent experiments. **b**, The CD19⁺ population is shown in the viSNE plots. Data represent means ± SD. Student's *t*-test or Tukey's multiple comparisons test was applied for statistical analysis. *, **, ***: significance at *p*<0.05, 0.01, 0.001. Fig. S3



Fig. S3: Bm $\Delta v j b R$::tnaA in combination with T_{regs} delays the progression of CIA.

a, Arthritis Score and **b**, arthritis incidence derived from treatment of CIA mice with indicated treatment strategies. Mice were inoculated with an emulsion of CFA and collagen on Day 0 followed by $Bm\Delta v j b R$::*tnaA* (5 x 10⁷ cfu) and/or indole treatment (20 mg/kg) on Day 21 followed by T_{reg} cell transfer on Day 25. The T_{reg} only group of mice received only T_{reg} cells without any other treatment. A booster (repeat) injection of CFA + Collagen was also administered to the mice on Day 21 to enhance CIA. Data represent means \pm SD. Student's *t*-test or Tukey's multiple comparisons test was applied for statistical analysis. ***: significance at *p* < 0.001.

| Population | Cell type | Ctrl | T _{reg} | Bm <i>∆vjbR</i> <i>∷tnaA</i> + T _{req} |
|------------|---------------------------|--------|------------------|---|
| 1 | CD40L hi CD25 lo | 8.6 % | 18.7 % | 72.7 % |
| 2 | CD25 hi Tim3 hi Ki67 hi | 34.9 % | 20.4 % | 44.7 % |
| 3 | D45 lo CD44 mid | 34.7 % | 22.2 % | 43.1 % |
| 4 | CD45 lo CD44 lo | 34.3 % | 27.9 % | 37.8 % |
| 5 | CD44 hi CD160 mid | 28.0 % | 36.0 % | 36.0 % |
| 6 | CD3 hi CD8hi CD25 lo | 31.8 % | 33.3 % | 34.9 % |
| 7 | CD19 hi CD62L lo | 32.7 % | 33.6 % | 33.7 % |
| 8 | CD4 hi CD25 lo | 31.9 % | 36.8 % | 31.3 % |
| 9 | CD4 hi CD25 mid CTLA4 lo | 37.0 % | 32.0 % | 31.0 % |
| 10 | CD25 hi PD-L1 hi | 47.1 % | 22.9 % | 30.0 % |
| 11 | CD8 hi CD62L lo | 38.2 % | 32.4 % | 29.4 % |
| 12 | CD19 hi CD40L hi | 40.6 % | 36.7 % | 22.7 % |
| 13 | CD19 hi PD-1 mid CTLA4 hi | 46.6 % | 32.3 % | 21.1 % |
| 14 | CD19 hi CD40L hi | 32.1 % | 47.4 % | 20.5 % |
| 15 | CD25 hi CD140 hi | 20.1 % | 60.3 % | 19.6 % |
| 16 | CCR7 hi PD-1 lo | 53.1 % | 28.0 % | 18.9 % |
| 17 | CD4 mid PD-L1 hi | 55.2 % | 29.3 % | 15.5 % |
| 18 | CD19 hi PD-1 lo CD40L lo | 76.0 % | 22.3 % | 1.68 % |

Supplementary Table 1. A list of different immune cell types which were differentiated using the tSNE analysis and their proportion in different treatment groups.

| Ab | Clone | Fluorophore | Source | |
|-------------------|--------------|----------------------|--------------------------|--|
| Ghost Dye Red 710 | | Ghost Dye Red 710 | Tonbo Biosciences | |
| CD45 | 30-F11 | FITC | Tonbo Biosciences | |
| CD8a | 53-6.7 | BUV395 | BD Biosciences | |
| CD4 | GK1.5 | eFluor 450 | Thermo Fisher Scientific | |
| CD3 | 17A2 | APC-Fire 810 | BioLegend | |
| CD19 | 1D3 | BUV805 | BD Biosciences | |
| MHC II | M5/114.15.2 | Violet Fluor 500 | Tonbo Biosciences | |
| CD160 | 7H1 | APC | BioLegend | |
| PD-L1 | MIH5 | Super Bright 780 | Thermo Fisher Scientific | |
| CTLA-4 | UC10-4F10-11 | PE-Cy7 | Tonbo Biosciences | |
| PD-1 | 29F.1A12 | PE-Dazzle 594 | BioLegend | |
| Lag-3 | C9B7W | BUV661 | BD Biosciences | |
| TIM-3 | 5D12/TIM-3 | Brilliant Violet 605 | BD Biosciences | |
| CD44 | IM7 | PerCP | BioLegend | |
| CD62L | HRL1 | BUV737 | BD Biosciences | |
| Ki-67 | B56 | Brilliant Violet 711 | BD Biosciences | |
| CCR7 | 4B12 | PE | BioLegend | |
| CD69 | H1.2F3 | BUV563 | BD Biosciences | |
| CD25 | PC61 | Brilliant Violet 650 | BioLegend | |
| CD40L | MR1 | BB700 | BD Biosciences | |
| CD28 | 37.51 | BUV496 | BD Biosciences | |

Supplementary Table 2: List of Abs used in CyTEK assay